奥沙利铂在卵巢癌治疗中的研究进展
作者：尹如铁;王丹青;谢聪;李玉玲;
Author：
收稿日期： 年卷（期）页码：2009,24(04):-433-436
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：奥沙利铂;卵巢癌;铂类衍生物;化疗
Key words：
基金项目：成都市科技局基金(No.0040215301086)
中文摘要
卵巢癌的早期诊断困难,初次治疗后有80%以上患者复发,5年生存率低。目前泰素联合卡铂方案为公认的、标准的一线化疗方案,尚无标准的二线化疗方案。奥沙利铂属于第三代铂类衍生物,与第一、第二代铂类无交叉耐药,可作为卵巢癌二线化疗的药物之一。综述奥沙利铂在卵巢癌治疗中的研究现状。
参考文献
[1]Chollet P,Bensmaine A,Brienza S,et al.Single agent activity ofOxaliplatin in heavily pretreated advanced epithelial ovarian canc-er[J].Ann Oncol,1996,7(10):1065-1070.
[2]Mani S,Graham MA,Bregman DB,et al.Oxaliplatin:a review ofevolving concepts[J].Canc Invest,2002,20(2):246-263.
[3]Raymond E,Faivre S,Woynarowski JM,et al.Oxaliplatin:Mecha-nism of action and antineoplastic activity[J].Semin Oncol,1998,25(15):4-12.
[4]Woynarowski JM,Faivre S,Herzig MCS,et al.Oxaliplatin-in-duced damage of cellular DNA[J].Mol Pharm,2000,58(5):920-927.
[5]Ozols RF,Bundy,Greer BE,et al.Phase III trials of Carboplatinand Paclitaxel compared with Cisplatin and Paclitaxel in patientswith optimally resected stage III ovarian cancer:a GynecologicOncology Group study[J].J Clin Oncol,2003,21(15):3194-3200.
[6]The International Collaborative Ovarian Neoplasm Group(ICONInvestigator).Paclitaxel plus Carboplatin versus standard chemo-therapy with either single-agent Carboplatin or Cyclophospha-mide,Doxorubicin,and Cisplatin in women with ovarian cancer:the ICON3 randomised trial[J].Lancet,2002,360(3):505-515.
[7]ICON3:Paclitaxel plus Carboplatin versus standard chemotherapywith either single?agent Carboplatin or Cyclophosphamide,Doxorubicin,and Cisplatin in women with overian cancer:the I-CON3randomised trial[J].Lancet,2002,360(9332):505-515.
[8]Ozols RF.Gynecologic oncology group trials in ovarian carcinoma[J].Semin Oncol,1997,24(1 suppl 2):S2-10-2.
[9]Fracasso PM,Blessing JA,Morgan MA,et al.Phase II study ofOxaliplatin in platinum-resistant and refractory ovarian cancer:a Gynecologic Oncology Group study[J].J Clin Oncol,2003,21(14):2856-2859.
[10]Delaloge S,Laadem A,Taamma A,et al.Pilot study of the Pacli-taxel,Oxaliplatin,and Cisplatin combination in patients with ad-vanced/recurrent ovarian cancer[J].Am J Clin Oncol,2000,23(6):569-574.
[11]Viens P,Petit T,Yovine A,et al.Aphase II study of a Paclitaxeland Oxaliplatin combination in Platinum-sensitive recurrent ad-vanced ovarian cancer patients[J].Ann Oncol,2006,17(3):429-436.
[12]Recchia F,De Filippis S,Saggio G,et al.Phase I study of lipo-somal Doxorubicin and Oxaliplatin as salvage chemotherapy in ad-vanced ovarian cancer[J].Anticanc Drugs,2003,14(8):633-638.
[13]Recchia F,Saggio G,Amiconi G,et al.A multicenter phase IIstudy of pegylated liposomal Doxorubicin and Oxaliplatin in recur-rent ovarian cancer[J].Gynecol Oncol,2007,106(1):164-169.
[14]Valerio MR,Tagliaferri P,Raspagliesi F,et al.A phase II studyof pegylated liposomal Doxorubicin Oxaliplatin and Cyclophospha-mide as second-line treatment in relapsed ovarian carcinoma[J].Int J Gynecol Canc,2006,16(Supp1 1):79-85.
[15]Nicoletto MO,Falci C,Pianalto D,et al.Phase II study of pegy-lated liposomal Doxorubicin and Oxaliplatin in relapsed advancedovarian cancer[J].Gynecol Oncol,2006,100(2):318-323.
[16]Raspagliesi F,Zanaboni F,Vecchione F,et al.Gemcitabine com-bined with Oxaliplatin(GEMOX)as second-line chemotherapyin patients with advanced ovarian cancer refractory or resistant toplatinum and taxane[J].Oncology,2004,67(5):376-381.
[17]Steer CB,Chrystal K,Cheong KA,et al.Gemcitabine and Oxali-platin followed by Paclitaxel and Carboplatin as first line therapyfor patients with suboptimally debulked,advanced epithelial ovar-ian cancer.A phase II trial of sequential doublets.The GO-First Study[J].Gynecol Oncol,2006,103(2):439-445.
[18]Harnett P,Buck M,Beale P,et al.Phase II study of Gemcitabineand Oxaliplatin in patients with recurrent ovarian cancer:an Aus-tralian and New Zealand Gynaecological Oncology Group study[J].Int J Gynecol Canc,2007,17(2):359-366.
[19]Tortora G,Ciardiello F,Damiano V,et al.Preclinical and phaseI study of Oxaliplatin and Topotecan in combination in humancancer[J].Ann Oncol,2002,13(3):392-398.
[20]Elkas JC,Winter WE 3rd,Chernofsky MR,et al.A phase I trialof Oxaliplatin and Topotecan in recurrent ovarian carcinoma[J].Gynecol Oncol,2007,104(2):422-427.
[21]Pectasides D,Pectasides M,Farmakis D,et al.Oxaliplatin plushigh-dose leucovorin and 5-fluorouracil(FOLFOX4)in plati-num-resistant and taxane-pretreated ovarian cancer:a phase IIstudy[J].Gynecol Oncol,2004,95(1):165-172.
[22]Sundar S,Symonds RP,Decatris MP,et al.Phase II trial of Oxali-platin and 5-Fluorouracil/Leucovorin combination in epithelialovarian carcinoma relapsing within 2 years of platinum-basedtherapy.[J].Gynecol Oncol,2004,94(2):502-508.
【关闭】
